A clinical trial to study the effects of adding the novel treatment rTMS (application of magnetic fields to brain) for people suffering from obsessive-compulsive disorder who have not improved adequately with standard treatment with medicines.

Augmentation effect of low frequency-repetitive transcranial magnetic stimulation over supplementary motor area in obsessive compulsive disorder: a randomized controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2012/09/003031

Enrollment

Registered

2012-09-28

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Obsessive-compulsive disorder Health Condition 2: F42- Obsessive-compulsive disorder

Interventions

Intervention1: Repetitive Transcranial Magnetic stimulation (rTMS) : rTMS over supplementary motor area at 1Hz, 20 minutes given in 4 trains of 300 seconds each, with inter-train interval of 2 minute

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age- = 18yrs 2. Diagnosed OCD since at least one year – (confirmed with MINI) 3. Partial (25-35% reduction in YBOCS score) or no response ( 4. Has current residual symptoms (YBOCS – =16 / CGI-I - = 4) 5. No medication/treatment change since 6 weeks

Exclusion criteria

Exclusion criteria: 1. Contraindications for TMS i) Metal implants ii) Pacemaker iii) Primary seizure disorder 2. Comorbid psychotic, bipolar disorder 3. Comorbid severe depression (HAM-D = 28) 4. Comorbid active substance use disorder (apart from nicotine use disorder) 5. Medication change (for OCD) within past 6 weeks 6. Undergoing concomitant behavioural therapy 7. Unstable medical conditions, pregnancy, or breastfeeding

Design outcomes

Primary

Measure	Time frame
Yale-Brown Obsessive Compulsive Scale (YBOCS) Timepoint: 0,1,2,3 ,12 weeks since initiation of treatment	—

Secondary

Measure	Time frame
1) Clinical Global Impression-Severity of illness (CGI-S) 2)Hamilton depression Rating scale (HAM-D) – 17 item 3)Hamilton Anxiety Rating Scale (HAM-A) 4)Mini-Mental Status Examination (MMSE) 5)UKU Side-effect Rating Scale Timepoint: 1) to 4)- 0,1,2,3,12 weeks after initiation of treatment 5) - 1,2,3,12 weeks after initiation of treatment	—

Countries

India

Contacts

Public ContactA Shyam Sundar

National Institute of Mental Health & Neurosciences NIMHANS

a.shyamsundar@gmail.com9008600112

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026